TransMedics, a US-based medical device producer focused on making the transport of organ transplants safer, has closed a $51.2m funding round co-led by pharmaceutical firm Pharmstandard International.

Pharmstandard, which participated through its InBio Ventures unit, co-led the round alongside Fayerweather Fund, Ervington Investments and BioStar Ventures. Biotechnology company Lung Biotechnology PBC, Abrams Capital, Flagship Ventures and Kleiner Perkins Caufield & Byers also took part.

Founded in 1998, TransMedics has created a warm blood perfusion system for the transport of organs.…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?